William C. Zamboni

Ph.D., School of Pharmacy, UNC-Chapel Hill, Clinical Research, Molecular Therapeutics

William C. Zamboni

Ph.D.
School of Pharmacy
UNC-Chapel Hill
Clinical Research
Molecular Therapeutics
Genetics Medicine Building
843-6665


Area of interest

Dr. Zamboni's research program is part of the Division of Pharmacotherapy and Experimental Therapeutics in the School of Pharmacy at the University of North Carolina (UNC) and the Molecular Therapeutics Program in the UNC Lineberger Comprehensive Cancer Center. He has been involved in translational studies of anticancer agents for several years. His research interests focus on applying pharmacokinetic, pharmacodynamic, and pharmacogenetic principles to optimized the chemotherapeutic treatment of cancer. Information obtained from preclinical and clinical translational studies can greatly add to the understanding of the pharmacology of anticancer agents, permit individualization of chemotherapeutic treatment based on pharmacokinetic, pharmacodynamic, and pharmacogenetic principles, and allow for the rational design of therapeutic regimens.

Dr. Zamboni's research also focuses on developing liposomal and nanoparticle anticancer agents, and evaluating the relationship between the disposition of these agents and the reticuloendothelial system. As part of these studies, Dr. Zamboni has used microdialysis to evaluate tumor extracellular fluid disposition of anticancer agents and factors affecting delivery and removal of anticancer agents. Dr. Zamboni has also developed methods and technologies to differentiate between inactive-encapsulate and active-released forms of drugs, and his laboratory evaluates potential phenotypic probes for pharmacokinetic and pharmacodynamic disposition of liposomal and nanoparticles. Major goals of research in these areas are to develop anticancer drugs with enhanced solid tumor penetration, to develop methods to increase the tumor delivery of liposomal and nanoparticle agents, and to generate administration schedules to enhance selective tumor uptake.

Awards and Honors

Director, GLP Analytical Facility, Center for Experimental Therapeutics, School of Pharmacy and UNC Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, 2008 to present.

Associate Professor, Division of Pharmacotherapy and Experimental Therapeutics, School of Pharmacy, University of North Carolina, Chapel Hill, NC, 2008 to present.

Member, Molecular Therapeutics Program, Lineberger Comprehensive Cancer Center, University of North Carolina, Chapel Hill, NC, 2008 to present.

Member, Institute for Pharmacogenomics and Individualized Therapy, University of North Carolina, Chapel Hill, NC, 2008 to present.

Member, Carolina Center of Cancer Nanotechnology Excellence, University of North Carolina, Chapel Hill, NC, 2008 to present.

American College of Clinical Oncology Aventis Oncology Fellowship entitled Evaluation of the Tumor Disposition of Cisplatin using Microdialysis in Patients with Melanoma, 2001.

Papa Johns/V Foundation Award for Factors Affecting the Tumor Disposition of Anticancer project, 2000.

Link to Publications on Reach NC site

Find publications on Pubmed